FlandersBio informs you about important regional and national life sciences news. Send us your news. If your news is of interest to the life sciences community, we will post it on our website.
FlandersBio informeert u over belangrijk nieuws op het vlak van de biowetenschappen. Bezorg ons jouw nieuwtjes. Als het interessant is voor de sector, zullen wij het op onze website plaatsen.
BioPontis Alliance for Rare Diseases today announces receipt of a large three year donation from the prestigious Baillet Latour Fund (BLF) in Belgium. BioPontis Alliance has the mission to translate biomedical research into therapies for rare diseases, and underwent rigorous vetting from BLF’s high level Board and medical advisors. The funding is offered to BioPontis as part of BLF’s commitment to stimulating human excellence through seed funding of transformational ideas for societal improvement. The donation is also intended to encourage other funders to support BioPontis. read more
BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the bone cell therapy company addressing high unmet medical needs in the field of bone fracture repair and bone fracture prevention, today announces it has been granted an additional EUR 2 million in non-dilutive funding* to support its research programs. The funding comes from the Walloon Region by decision of the Minister for Economy, Industry, Innovation and New technologies, Mr Jean-Claude Marcourt, bringing the total of non-dilutive funding to EUR 5 million for the full year 2015. read more
Biocartis Group NV (the "Company" or "Biocartis"), an innovative molecular diagnostics company (Euronext Brussels: BCART), announces today that 36,328 new shares were issued as a result of the exercise of stock options under the 2013 Plan for employees, consultants and management members. In view hereof, in accordance with article 15 of the Belgian Act of 2 May 2007 on the disclosure of major shareholdings in issuers shares of which are admitted to trading on a regulated market and laying down miscellaneous provisions (the "Belgian Act"), the outstanding share capital and outstanding voting securities of the Company can be summarised as follows: read more
BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the bone cell therapy company addressing high unmet medical needs in the field of bone fracture repair and bone fracture prevention, today announces its financial calendar for 2016. read more
ESPERITE N.V. (Euronext: ESP, 'ESPERITE', or 'the Group') announces the issuance of a convertible loan note of EUR 925,565 to Mr. Frédéric Amar, ESPERITE's Chief Executive Officer and largest shareholder. The issuance converts a payment obligation that ESPERITE has towards Mr. Amar relating to remuneration and pre-paid investments and expenses into the note. Mr. Amar has not participated in the decision-making of the Board of Directors regarding the issuance of the note. read more
TiGenix NV (Euronext Brussels: TIG) publishes information in accordance with articles 15 and 18 of the Belgian Law of May 2, 2007 regarding the publication of major holdings in issuers whose securities are admitted to trading on a regulated market and including various provisions (the Law) and the Royal Decree of February 14, 2008 regarding the publication of major holdings. read more
The Institute for Science and Technology (IWT) has granted Voxdale and Ergotrics 250,000 euros in support of an SME innovation project that aims to develop inflatable technologies for industrial and healthcare applications. read more
Galapagos NV (Euronext & NASDAQ: GLPG) announced today that GLPG1972, a first-in-class candidate drug aiming at treating osteoarthritis, has been dosed in a Phase 1 First-in-Human study. GLPG1972 has a novel mode of action discovered by Galapagos under its collaboration agreement with Servier, and has potential application in osteoarthritis. Galapagos will receive a €3.5 million milestone payment from Servier for this achievement. read more
Celyad (Euronext Brussels and Paris, and NASDAQ: CYAD), a leader in the discovery and development of engineered cell therapies, with clinical programs in cardiovascular disease and immuno-oncology, today provided an update on key clinical and operational initiatives for the three-month period ended 30 September 2015. read more
Biocartis (Euronext Brussels: BCART), een innovatief bedrijf in de moleculaire diagnostiek, kondigt vandaag een business update aan voor Q3 2015 en vooruitzichten voor de komenden maanden. read more